Complement Factor D Inhibitor global drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	9,796,741	⤷ Start Trial		Y		⤷ Start Trial
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	12,076,319	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: May 18, 2026

Complement factor D inhibitors sit in the terminal complement pathway for diseases driven by alternative-pathway activation. The patent and commercial landscape for this class is shaped by (1) rapid sequencing of first-in-class and follow-on mechanisms, (2) method- and formulation-layer “evergreening” around monoclonal antibody and small-molecule approaches, and (3) FDA exclusivity and Orange Book visibility timing that governs when generics or follow-on biologics can enter.

Because “complement factor D inhibitors” can map to multiple active ingredients and MoAs (true factor D inhibition vs. adjacent terminal complement and alternative-pathway targeting), the actionable patent map below focuses on factor D inhibition specifically and the competitive set most frequently co-compared with factor D programs: alternative-pathway complement control, terminal pathway inhibition, and local vs systemic complement suppression strategies.

Which drugs are complement factor D inhibitors and how do they compete commercially?

What is the product definition for “factor D inhibition” in the market

Factor D is a serine protease in the alternative complement pathway. A “complement factor D inhibitor” drug class typically includes agents that directly inhibit factor D activity, reducing cleavage of C3 and downstream amplification.

Commercial competition in this therapeutic space depends less on label wording and more on:

Positioning vs C3 inhibitors and terminal pathway inhibitors (C5 blockade)
Oral vs injectable administration
Background standard of care (complement-mediated hemolysis, kidney disease, ocular complement-driven conditions)
Rate of adoption in biomarker-defined populations (alternative-pathway activity)

How pricing and access dynamics shape adoption

Key market forces for this class:

Payor coverage tied to demonstrable complement-mediated disease control endpoints (hemolysis markers, proteinuria, relapse rates, visual outcomes where applicable).
Admin convenience: oral small molecules vs outpatient infusions or injection workflows.
Biosurveillance: immunogenicity and long-term safety monitoring requirements for biologics, influencing payer comfort and contracting.

How the competitive set usually frames substitution risk

Factor D inhibitors compete on:

Depth of complement pathway suppression (alternative pathway amplification vs terminal blockade)
Safety profile (infection risk and injection-related risk)
Speed of response in acute disease states (where trial endpoints allow cross-trial inference)

What patents protect complement factor D inhibitors: drug substance, formulations, and methods of use?

Core patent “buckets” that typically exist

A robust factor D inhibitor estate usually contains:

Composition of matter for the active ingredient (small molecule or antibody/Fab or engineered construct)
Pharmaceutical compositions (stabilizers, buffers, lyophilization matrices, fill-finish compatible formulations)
Methods of treatment (indications, patient selection, dosing regimens, combinations)
Manufacturing (cell line/bioreactor parameters for biologics; polymorph/crystal form control for small molecules)
Use of biomarkers (diagnostic or enrichment criteria, complement activation markers)
Combination therapy patents (factor D inhibitor + anti-complement agent, immunosuppressant, or standard of care)

Where patent coverage is most litigated

Litigation risk typically concentrates where generic or biosimilar substitution can pressure exclusivity:

Method-of-use patents when the label is narrow but clinical practice can broaden use.
Formulation patents when switching from one delivery form to another could be framed as “non-infringing” unless properly insulated.
Dosing regimen patents when trials establish a differentiated titration or maintenance schedule.

Patent strength indicators used by challengers

In factor D inhibitor estates, the most challengeable elements tend to be:

“Late-stage” incremental claims that recite dosing amounts without a deep structural novelty
Broad method claims lacking tight linkage to a specific mechanism, patient phenotype, or biomarker threshold

Which companies hold the key patent estates for factor D inhibitors?

Estate ownership patterns

The factor D landscape commonly shows:

Originator biopharm companies hold the principal composition-of-matter and engineered biologic construct portfolios.
Specialty pharma or contract manufacturing organizations may own process/manufacturing improvements.
Academic groups rarely own core factor D inhibition composition claims but can own biomarker and selection patents.

What to expect in licensing and cross-licensing

This class frequently uses:

Early-stage technology licensing for antibody engineering or discovery platforms
Co-development agreements for niche indications
Back-end assignment structures that consolidate method-of-use rights at commercialization entities

When does complement factor D inhibitor exclusivity end: patent expiration and FDA exclusivity timelines?

How exclusivity is structured for this class

Exclusivity often combines:

Basic patent term for composition-of-matter (20-year from earliest non-provisional filing, subject to PTA)
Patent term adjustment (PTA) driven by FDA review clock
FDA exclusivity (new molecular entity, new clinical investigations, approval-based exclusivity)

Launch-to-challenge timing dynamics

A practical timeline for this class is:

Year 0-2: composition-of-matter dominates protection; formulation and method claims appear as additional claims issue.
Year 2-6: Orange Book listings expand with follow-on patents.
Year 6-10: Paragraph IV window opens where ANDA/BLA equivalents target expiration of earliest listed patents.
Year 10+: most generic pressure shifts to later-expiring method-of-use and formulation patents unless those are weak or non-infringing workarounds exist.

How courts typically affect “real” exclusivity

Litigation outcomes control practical barriers:

Invalidation or narrowing of method-of-use claims can accelerate market entry even with intact composition patents.
Settlement agreements can delay entry beyond the theoretical patent calendar.

What is the Orange Book status for complement factor D inhibitors and how many patents are listed?

Orange Book listing density as an entry predictor

For high-cost complement therapies, it is common to see multiple listed patents across:

Active ingredient
Formulation
Method of use

Entry predictors:

Number of listed patents tied to the approved NDC
Whether multiple patents expire at the same time or staggered years
Whether method-of-use patents are listed and cover the exact approved indications

Featured snippet answer (what matter most)

The Orange Book entry count and stagger pattern are the most direct indicators of how long generics or follow-on biologics face a “patent wall” after first entry attempt.

How strong is the patent estate for factor D inhibitors: claim coverage and vulnerability?

Strength levers

Patent estates for factor D inhibitors tend to be strong where:

Claims are directly tied to active-ingredient structure and binding/inhibition mechanism.
Manufacturing or stability claims support non-trivial process switching.
Method-of-use claims link to biomarker enrichment and dose regimens validated in clinical trials.

Vulnerability levers

Estates weaken where:

Broad method claims cover a wide patient population without clear clinical support.
Dependent claims depend on functional limitations that become obvious or non-distinguishable over prior art.
Formulation claims rely on routine excipients and standard stabilization approaches.

Litigation posture expectations

Where estates are strong, challengers generally pursue:

Non-infringement design-arounds
Carve-outs in method-of-use claims
Alternative dosing strategies to avoid “use” infringement

What patent litigation affects complement factor D inhibitors: Paragraph IV, settlements, and injunction risk?

What a “typical” litigation sequence looks like

For small-molecule factor D inhibitors, a typical path includes:

ANDA filing tied to a Paragraph IV certification for one or more listed patents
FDA automatic stay (until the statutory period or a court decision)
District court decisions on validity and infringement
Settlement with agreed entry date and licensed exclusivity carve-outs

For biologic factor D inhibition, the sequence can differ:

BLA pathway for follow-on biologics (or biosimilar reference product reliance)
Patent dance with disclosure of infringement contentions
Settlement agreements controlling timing of biosimilar launch

Key variables that determine outcome

Claim construction centered on mechanism or functional inhibition standards
Whether the challenger’s product can plausibly be “non-infringing” while maintaining similar pharmacology
Validity challenges tied to prior art disclosures on factor D inhibition

What generic entry risks exist for factor D inhibitors: design-arounds and non-infringement strategies?

Small molecule risk profile

Main generic entry risks:

Structural claim barriers: close analogs may still infringe composition claims.
Polymorph/crystal form barriers: switching forms does not always avoid infringement if claims cover “any form” or functional constraints.
Formulation stability: generic wetting, buffering, and solubility agents may implicate formulation patents.

Typical workaround:

Seek a launch that avoids infringing formulations by using non-covered excipient systems if allowed by label and comparability.

Biologics risk profile

Main biosimilar risks:

Epitope and binding similarity thresholds
Glycosylation and stability profiles
Manufacturing comparability requirements that can constrain “design-around” freedom

Typical workaround:

Use a biosimilar approach that demonstrates functional equivalence while avoiding method-of-use claim infringement via label positioning.

How do factor D inhibitors compare with C3 inhibitors and C5 inhibitors for patent and commercial defensibility?

Mechanism-driven differentiation

Factor D inhibitors dampen alternative-pathway amplification upstream.
C3 inhibitors reduce central complement cleavage.
C5 inhibitors block terminal complement effect.

Patent defensibility comparison

Upstream inhibitors often carry strong method-of-use positioning due to biomarker-defined alternative pathway activity.
Terminal inhibitors have broader historical clinical use patterns and may face more labeling breadth arguments, which can affect method-of-use patent enforceability.

Commercial defensibility comparison

Oral factor D inhibitors can establish switching resistance via patient preference and dosing convenience.
Injectables often compete through health system pathways (infusion center vs home injection vs specialty pharmacy).

What formulations are protected by patents for factor D inhibitors?

Common protected formulation categories

Lyophilized antibody cakes and reconstitution systems
Long-acting injectable formulations (higher viscosity, stabilizers, surfactants)
Oral small-molecule solid forms (crystal forms, solvate-free constraints, dissolution rate profiles)
Combination co-pack formulations (less common, but protected when used)

Why formulation patents matter even when generics exist

Even when active ingredient composition is challenged successfully, formulation patents can:

Delay final manufacturing approval
Limit permissible excipients under comparability protocols
Create injunction risk if a generic is marketed with a formulation that infringes

What method-of-use patents protect factor D inhibitors and how do they affect label design?

Method-of-use claim patterns

Indication-specific claims (approved disease entity)
Biomarker-defined claims (alternative pathway activation markers)
Patient selection based on prior therapy response
Dosing schedules tied to maintenance or ramp-up phases
Combination with immunomodulators or standard-of-care regimens

How label design can reduce infringement exposure

Originators may pursue narrow label language where method claims exist. Challengers can attempt:

Label carve-outs
Different dosing schedules
Different patient populations to avoid “use” infringement

What regulatory status do factor D inhibitors have and what does it mean for market timing?

FDA pathway impacts on timelines

Market entry timing depends on:

Whether the original drug got fast-track, breakthrough designation, or priority review
Whether supplementary approval cycles added new indications (and new patent listings)
Whether the reference product has multiple NDCs with different formulation strengths

Biosimilar and generic pathway dependence

ANDAs require therapeutic equivalence and matching active ingredient plus permissible formulation parameters.
Biosimilars require high similarity and can still face method-of-use patent barriers even if the product is approved on an abbreviated pathway.

Key timelines: how to map exclusivity end dates to patent filing calendars

How to build a business-ready entry timeline

For factor D inhibitors, the most decision-relevant timeline is a stacked view of:

Earliest filing date (for 20-year max)
PTA adjustments (calendar shift)
Orange Book “listed patent” stagger expiration by NDC strength
FDA exclusivity end date (NME/NCI as applicable)
Patent litigation “real-world” stay and settlement launch dates

Because this class has multi-layer estates, the earliest composition patent expiry rarely ends market barriers alone.

Key Takeaways

Complement factor D inhibitors rely on stacked protection: composition of matter plus formulation and method-of-use patents that extend practical exclusivity past basic calendar expiration.
Commercial adoption is driven by dosing convenience, payor coverage tied to complement-mediated endpoints, and patient selection based on alternative-pathway biology.
Entry risk for generics or biosimilars is less about a single expiration date and more about Orange Book listing density, method-of-use claim strength, and litigation/settlement outcomes.
For enforcement and licensing, the highest value patent layers are method-of-use claims tied to biomarker-defined populations and formulation or manufacturing claims that constrain “workaround” freedom.

FAQs

How do Orange Book “listed patents” for complement factor D inhibitors differ from unlisted patent family members in enforcement?
What Paragraph IV certification strategies do generic filers use against method-of-use patents for complement factor D inhibitors?
Do biomarker-driven indications for factor D inhibitors increase enforceability of method-of-use claims?
When biosimilars of complement inhibitors launch, what barriers remain if composition patents expire but method-of-use patents persist?
How do formulation patent claims influence FDA approval outcomes for follow-on products even when active ingredient patents are challenged?

References (APA)

FDA. (n.d.). Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration.
FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
U.S. Patent and Trademark Office. (n.d.). Patent term, patent term adjustment, and regulatory review factors. USPTO.